J Korean Rheum Assoc.
2006 Sep;13(3):230-235.
Experience of Rituximab Treatment in Two Patients with Severe Systemic Lupus Erythematosus
- Affiliations
-
- 1Department of Internal Medicine, Pusan National University College of Medicine, Korea. ksimd@pusan.ac.kr
- 2Department of Internal Medicine, Pusan Medical Center, Busan, Korea.
Abstract
- Rituximab is a chimeric monoclonal antibody for human B lymphocyte subset CD20 and has recently been used for treatment of autoimmune disease such as rheumatoid arthritis and systemic lupus erythematosus (SLE). We report the experiences of rituximab treatment in two patients with severe SLE. The first case is 16-year-old female patient with hemolytic anemia, thrombocytopenia and acute renal failure due to aggravation of lupus nephritis, and the second case is 30-year-old female pregnant patient with diffuse alveolar hemorrhage after preterm premature rupture of fetal membranes. All two patients responded to rituximab and maintained symptom free state.
Keyword
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Catastrophic Antiphospholipid Syndrome Associated with Systemic Lupus Erythematosus Successfully Treated with Rituximab: A Case Report
- A Case of Rituximab Therapy in Diffuse Alveolar Hemorrhage of Systemic Lupus Erythematosus Refractory to Steroid Pulse Therapy
- A Case Of Systemic Lupus Erythematosus Associated With Hyperthyroidism And Severe Retinopathy
- A Case of Lupus Enteritis That Developed during the Treatment of Systemic Lupus Erythematosus
- A Case of Transverse Myelitis as a First Manifestation of Systemic Lupus Erythematosus
